1-苄基-1H-吡啶并[2,3-d][1,3]噁嗪-2,4-二酮 | 97484-73-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 1-苄基-1H-吡啶并[2,3-d][1,3]噁嗪-2,4-二酮
• 英文名称: N-benzyl-2H-pyrido<2,3-d><1.3>oxazine-2,4 1H-dione
• 英文别名: N-benzyl 3-azaisatoic anhydride；1-benzyl-1H-pyrido[2,3-d][1,3]oxazine-2,4-dione；1-benzyl-2H-pyrido[2,3-d][1,3]oxazine-2,4(1H)-dione；1-benzylpyrido[2,3-d][1,3]oxazine-2,4-dione
• CAS: 97484-73-6
• 化学式: C₁₄H₁₀N₂O₃
• 分子量: 254.245
• InChiKey: IOTFENHDTBFXDO-UHFFFAOYSA-N

物化性质

• 熔点：
  152-158 °C
• 沸点：
  446.1±47.0 °C(Predicted)
• 密度：
  1.390±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  59.5
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  1-苄基-1H-吡啶并[2,3-d][1,3]噁嗪-2,4-二酮 在 sodium hydride 作用下， 以 N,N-二甲基乙酰胺 、 甲苯 为溶剂， 反应 7.0h， 生成 1-Benzyl-4-hydroxy-2-oxo-1,2-dihydro-[1,8]naphthyridine-3-carboxylic acid (2-sulfamoyl-phenyl)-amide
  参考文献：
  名称：

  Inhibitors of HCV NS5B polymerase: synthesis and structure–activity relationships of N-1-heteroalkyl-4-hydroxyquinolon-3-yl-benzothiadiazines

  摘要：

  N-1-Alkylamino and N-1-alkyloxy-4-hydroxyquinolon-3-yl benzothiadiazines were synthesized and evaluated as inhibitors of genotype 1 HCV polymerase. The N-1-alkyloxy derivatives were not potent inhibitors, however N-1-alkylamino derivatives displayed comparable potency to carbon analogs. Analogs with aliphatic substituents were significantly more potent than those with benzylic substituents against genotype la polymerase. The most potent inhibitors contained small alkyl or carbocyclic substituents and exhibited IC50's of 50-100 and 200-400 nM against genotype 1 b and 1 a HCV polymerase, respectively. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.01.071
• 作为产物：
  描述：

  2-乙酰氨基-5-溴-6-甲基吡啶 在 lead(IV) acetate 、 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 3.0h， 生成 1-苄基-1H-吡啶并[2,3-d][1,3]噁嗪-2,4-二酮
  参考文献：
  名称：

  Reactions of α,ω-bis(bromomagnesio)alkanes with heterocyclic anhydrides

  摘要：

  DOI：

  10.1016/s0040-4020(01)90000-6

文献信息

• Anti-infective agents
  申请人：——

  公开号：US20040087577A1

  公开（公告）日：2004-05-06

  Compounds having the formula 1 are hepatitis C (HCV) polymerase inhibitors. Also disclosed are a composition and method for inhibiting hepatitis C (HCV) polymerase, processes for making the compounds, and synthetic intermediates employed in the processes.

  具有公式1的化合物是丙型肝炎（HCV）聚合酶抑制剂。还公开了一种用于抑制丙型肝炎（HCV）聚合酶的组成和方法，用于制造这些化合物的过程，以及在这些过程中使用的合成中间体。
• [EN] SUBSTITUTED NAPHTHYRIDINE DERIVATIVES AS INHIBITORS OF MACROPHAGE MIGRATION INHIBITORY FACTOR AND THEIR USE IN THE TREATMENT OF HUMAN DISEASES<br/>[FR] DERIVES DE NAPHTYRIDINE SUBSTITUES SERVANT D'INHIBITEURS DE FACTEUR D'INHIBITION DE LA MIGRATION DES MACROPHAGES ET LEUR UTILISATION POUR TRAITER DES MALADIES HUMAINES
  申请人：AVANIR PHARMACEUTICALS

  公开号：WO2005021546A1

  公开（公告）日：2005-03-10

  Inhibitors of MIF having a naphthyridine backbone are provided which have utility in the treatment of a variety of disorders, including the treatment of pathological conditions associated with MIF activity. The inhibitors of MIF have the following structures: (Ia), (Ib), (Ic), (Id) including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein n, R, R1, R2, X, Y and Z are as defined herein. Compositions containing an inhibitor of MIF in combination with a pharmaceutically acceptable carrier are also provided, as well as methods for use of the same.

  提供具有萘啶骨架的MIF抑制剂，对多种疾病的治疗具有用处，包括治疗与MIF活性相关的病理状况。MIF的抑制剂具有以下结构：（Ia）、（Ib）、（Ic）、（Id），包括立体异构体、前药和其药用可接受的盐，其中n、R、R1、R2、X、Y和Z如本文所定义。还提供含有MIF抑制剂的组合物，以及其使用方法。
• Substituted naphthyridine derivatives as inhibitors of macrophage migration inhibitory factor and their use in the treatment of human diseases
  申请人：Sircar Jagadish

  公开号：US20050124604A1

  公开（公告）日：2005-06-09

  Inhibitors of MIF having a naphthyridine backbone are provided which have utility in the treatment of a variety of disorders, including the treatment of pathological conditions associated with MIF activity. The inhibitors of MIF have the following structures: including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein n, R, R 1 , R 2 , X, Y and Z are as defined herein. Compositions containing an inhibitor of MIF in combination with a pharmaceutically acceptable carrier are also provided, as well as methods for use of the same.

  提供了一种具有萘啶骨架的MIF抑制剂，其在治疗多种疾病中具有用途，包括治疗与MIF活性相关的病理状况。MIF抑制剂具有以下结构：包括立体异构体、前药和其药物可接受的盐，其中n、R、R1、R2、X、Y和Z如本文所定义。还提供了含有MIF抑制剂与药物可接受载体组合的组合物，以及使用它们的方法。
• SUBSTITUTED NAPHTHYRIDINE DERIVATIVES AS INHIBITORS OF MACROPHAGE MIGRATION INHIBITORY FACTOR AND THEIR USE IN THE TREATMENT OF HUMAN DISEASES
  申请人：Sircar Jagadish

  公开号：US20070191388A1

  公开（公告）日：2007-08-16

  Inhibitors of MIF having a naphthyridine backbone are provided which have utility in the treatment of a variety of disorders, including the treatment of pathological conditions associated with MIF activity. The inhibitors of MIF have the following structures: including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein n, R, R 1 , R 2 , X, Y and Z are as defined herein. Compositions containing an inhibitor of MIF in combination with a pharmaceutically acceptable carrier are also provided, as well as methods for use of the same.

  提供了具有萘啶骨架的MIF抑制剂，其在治疗各种疾病中具有用途，包括治疗与MIF活性相关的病理条件。 MIF抑制剂具有以下结构：包括立体异构体，前药和其药学上可接受的盐，其中n，R，R1，R2，X，Y和Z如本文所定义。还提供了含有MIF抑制剂与药学上可接受的载体组合的组合物，以及使用它们的方法。
• Inhibitors of HCV NS5B polymerase: Synthesis and structure–activity relationships of N-1-benzyl and N-1-[3-methylbutyl]-4-hydroxy-1,8-naphthyridon-3-yl benzothiadiazine analogs containing substituents on the aromatic ring
  作者：Todd W. Rockway、Rong Zhang、Dachun Liu、David A. Betebenner、Keith F. McDaniel、John K. Pratt、David Beno、Debra Montgomery、Wen W. Jiang、Sherie Masse、Warren M. Kati、Tim Middleton、Akhteruzzaman Molla、Clarence J. Maring、Dale J. Kempf

  DOI：10.1016/j.bmcl.2006.04.022

  日期：2006.7

  A series of non-nucleoside HCV NS5B polymerase inhibitors based on the N-1-benzyl or N-1-[3-methylbutyl]-4-hydroxy-1,8-naphthyridon-3-yl benzothiadiazine core substituted in the D-ring aromatic moiety have been prepared and evaluated. Aromatic substituents extending from position 7 of the D-ring exhibited excellent potency against both genotypes 1a and 1b. (c) 2006 Elsevier Ltd. All rights reserved.